Sponsors - Payer Exchange Summit

Summit Sponsors

Diamond

Amgen

At Amgen Oncology, our mission to serve patients drives all that we do. That’s why we’re relentlessly focused on accelerating the delivery of medicines that have the potential to empower all angles of care and transform lives of people with cancer. Visit AmgenOncology.com to learn more.

Twitter
Facebook
LinkedIn
Instagram

Astellas

Astellas Pharma US, Inc. is a U.S. affiliate of Tokyo-based Astellas Pharma Inc., a pharmaceutical conducting business in more than 70 countries around the world. Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the U.S. and around the world. For more information on Astellas, please visit: www.astellas.com/us You can also follow us on

Twitter
Facebook
LinkedIn

Blueprint Medicines

Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering approved medicines directly to patients in the United States and Europe, and we are globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy.

Twitter

Bristol Myers Squibb

Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular, fibrosis and neuroscience. Our employees work every day to transform patients’ lives through science.

LinkedIn
Twitter
YOUTUBE
Facebook
Instagram

EMD Serono

At EMD Serono, science is at the heart of everything we do. It drives the discoveries we make and the technologies we create. Our employees are dedicated to making a positive difference in the lives of patients and their loved ones. EMD Serono is the healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada.

Genentech

For more than 40 years, we’ve been following the science, seeking solutions to unmet medical needs. As a proud member of the Roche Group, we make medicines to treat patients with serious medical conditions. For more information about Genentech visit gene.com.

Genmab

Genmab is an international biotechnology company with a core purpose guiding its unstoppable team to strive towards improving the lives of patients through innovative and differentiated antibody therapeutics. For more than 20 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

To help develop and deliver novel antibody therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. By 2030, Genmab’s vision is to transform the lives of people with cancer and other serious diseases with Knock-Your-Socks-Off (KYSO) antibody medicines.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on

Twitter

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to pursuing scientific invention to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.
ã 2022 Gilead Sciences, Inc. All rights reserved.

breastandbladder.com

Janssen Oncology

At Janssen Oncology, we’re shaping the future of cancer treatment and striving to change expectations of what a cancer diagnosis means. We are urgently committed to bringing transformational cancer solutions to the people who need them. Passionate about our work, we focus on making a positive impact on human health.

Lilly

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly’s commitment to people with cancer, please visit www.Lilly.com.

Merck

At Merck, our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer. The potential to bring new hope to people with cancer drives our purpose and our commitment. As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry across more than 30 tumor types.

This content is intended only for health care professionals of the United States, its territories, and Puerto Rico.

Facebook
Twitter
Instagram
LinkedIn
YouTube

Pharmacyclics

Pharmacyclics is an AbbVie company based in South San Francisco, California and focused on developing and commercializing small-molecule medicines for the treatment of cancers and immune-mediated diseases for which there is great unmet medical need. We seek to discover innovative therapies to improve standards of care and strive to help our patients rediscover the Magic of Normal.

Ruby

BeiGene

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 5,400+ employees around the world are committed to expediting the development of a diverse pipeline of novel therapeutics.

Cardinal Health

Cardinal Health offers new, innovative solutions to help community oncology practices strengthen their businesses, succeed in value-based care and deliver high-quality care for patients. Through a comprehensive tech suite in Navista^TM TS, we help practices confidently make the best decisions for improved patient outcomes and financial performance. Explore how we can help you reach your goals at Cardinal Health.

Incyte

Incyte is a global biopharmaceutical company that is focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines.
Since 2002, Incyte has remained committed to the relentless pursuit of science that can improve the lives of patients, make a difference in healthcare and build

sustainable value for our stakeholders. The Company is advancing a diversified portfolio of clinical candidates across Oncology and Inflammation & Autoimmunity.

Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

LinkedIn
Twitter
Facebook

Ipsen Biopharmaceuticals, Inc.

Ipsen Biopharmaceuticals, Inc. is a US affiliate of Ipsen SA, a global biotech company. At Ipsen Biopharmaceuticals, we are focused on developing and providing access to therapies for patients who suffer from extremely difficult-to-treat diseases. For more information on Ipsen in North America, please visit www.ipsenus.com. To report adverse events, call 1-855-463-5127.

Emerald

Coherus BioSciences

Coherus BioSciences is a leading global biologics platform company focused on delivering high-quality biosimilar therapeutics that can expand patient access to life-changing medicines in regulated markets worldwide. In 2018, the U.S. Food and Drug Administration approved Coherus’ biosimilarUDENYCA®(pegfilgrastim-cbqv).For additional information, please visit www.coherus.com.

Eisai Inc.

At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, and marketing capabilities. Our key areas of focus include oncology and neurology (dementia-related diseases and neurodegenerative diseases). To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on socials.

Twitter
LinkedIn

Jazz Pharmaceuticals

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company dedicated to developing medicines for people with serious diseases — often with limited or no options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. We are a leader in sleep disorders and epilepsy; further developing in movement disorders and PTSD; and focused on hematologic malignancies and solid tumors. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules, biologics, innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. For more information, please visit www.jazzpharmaceuticals.com and follow on socials.

Twitter

Bristol Myers Squibb

LinkedIN
Twitter
YOUTUBE
Facebook
Instagram

Novartis

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world. Find out more at www.novartis.com.

Takeda Oncology

At Takeda Oncology, we aspire to cure cancer, with inspiration from patients and innovation from everywhere. We ensure a tight connection from research to development to commercialization to meet the needs of the cancer community, optimizing our ability to bring potentially transformative medicines to patients. Our demonstrated leadership in the treatment of hematologic cancers and solid tumors combined with cutting-edge science through multiple platforms, partnerships and therapeutic approaches, enable us to bring novel medicines to patients worldwide.

For more information, visit www.takedaoncology.com.

Takeda Virtual Exhibit

Bristol Myers Squibb

LinkedIN
Twitter
YOUTUBE
Facebook
Instagram

Sapphire

Adaptive Biotechnologies

Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. Adaptive’s goal is to develop and commercialize immune-driven diagnostics and therapeutics tailored to each individual patient.

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit this link.

AstraZeneca

AstraZeneca in oncology

AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience.

AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit www.astrazeneca-us.com and follow the Company on

Twitter

Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. The Guardant Health screening portfolio, including the Shield™ test, aims to address the needs of individuals eligible for cancer screening.

LinkedIn
Twitter

Bristol Myers Squibb

LinkedIN
Twitter
YOUTUBE
Facebook
Instagram

Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies dedicated to the discovery, development, and commercialization of novel first-in-class drugs for the treatment of cancer and other diseases. Karyopharm’s Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. The company was founded in 2008 with a vision of pioneering a potentially new approach to treating patients with certain blood cancers.

MacroGenics

MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company’s flagship product for the treatment of HER2+ metastatic breast cancer was approved by the US Food and Drug Administration in December 2020.

MacroGenics generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics’ technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.

Bristol Myers Squibb

LinkedIN
Twitter
YOUTUBE
Facebook
Instagram

Topaz

AbbVie

At AbbVie, we strive to discover and develop medicines that deliver transformational improvements in cancer treatment by uniquely combining our deep knowledge in core areas of biology with cutting-edge technologies, and by working together with our partners – scientists, clinical experts, industry peers, advocates, and patients. We remain focused on delivering these transformative advances in treatment across some of the most debilitating and widespread cancers. We are also committed to exploring solutions to help patients obtain access to our cancer medicines. AbbVie’s oncology portfolio now consists of marketed medicines and a pipeline containing multiple new molecules being evaluated worldwide in more than 300 clinical trials and more than 20 different tumor types. For more information, please visit www.abbvie.com/oncology.

Pharmacosmos Therapeutics Inc.

Pharmacosmos Therapeutics Inc. is part of Pharmacosmos, a family owned, global business with over 50 years of experience in researching and developing innovative treatments. We develop, manufacture, and market medicine for the treatment of iron deficiency anemia, in addition to developing and producing advanced carbohydrates for pharmaceutical and technical uses. We have more than 10 years of international experience in the High Dose IV Iron Marketplace.

Seagen

Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company’s marketed products and robust pipeline, visit www.seagen.com and follow

Twitter

Servier Pharmaceuticals LLC

Servier Pharmaceuticals LLC is a commercial-stage company with a passion for innovation and improving the lives of patients, their families and caregivers. As a privately held company, Servier has the unique freedom to devote all of its time and energy towards patients who require our treatments, care and innovation in areas of unmet medical need.

As a leader in oncology, Servier is committed to finding solutions that will address today’s challenges. The company’s oncology portfolio includes innovative medicines designed to bring more life-saving treatments to a greater number of patients, across the entire spectrum of disease and in a variety of tumor types. Servier has significantly accelerated its investment in hard-to-treat cancers with more than 50% of its research and development dedicated to delivering significant advances in areas of high unmet need that may truly move the needle for our patients.

Servier believes co-creation is fundamental to driving innovation and is actively building alliances, acquisitions, licensing deals and partnerships that bring solutions and accelerate access to therapies. With the company’s commercial expertise, global reach, scientific expertise and commitment to clinical excellence, Servier Pharmaceuticals is dedicated to bringing the promise of tomorrow to the patients that we serve.

www.servier.us